1. Market Research
  2. > Healthcare
  3. > Diagnostics Market Trends
  4. > Future Horizons and Growth Strategies in the French Cancer Diagnostics Market 2015: Supplier Shares and Country Forecasts

Complete report $6,800.  DataPack (test volumes, sales forecasts, supplier shares) $4,350.

“Future Horizons and Growth Strategies in the French Cancer Diagnostics Market 2015” is a new strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years.  The report examines trends in the French cancer diagnostics markets; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers and market segment; profiles leading market players and potential entrants; and suggests alternative business expansion strategies for suppliers.
 
Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease.  During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field.  Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy.  The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion.

Business Opportunities and Strategic Recommendations

- Specific new product development opportunities with potentially
significant market appeal during the next five years.

- Design criteria for new products.

- Alternative market penetration strategies.

- Potential market entry barriers and risks.

Cancer Diagnostic Tests—Over 200 current and emerging assays including:

ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA,
Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG,
Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar,
Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone,
Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein,
Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin,
Tissue Polypeptide Antigen, and others.

Market Segmentation Analysis

- Sales and market shares of major suppliers,
by individual cancer diagnostic test.

- Five-year test volume and sales forecasts
for major cancer diagnostic tests by market segment, including:

- Hospitals
- Commercial/Private Laboratories

- Comprehensive market segmentation analysis, including review
of the market dynamics, structure, size, growth and major suppliers.

- Cancer statistics, etiology and recent developments.

Current and Emerging Products

- Review of over 200 current and emerging cancer diagnostic tests,
including:

- Biochemical Markers
- Oncogenes
- Growth Factors
- Hormones
- Colony Stimulating Factors
- Lymphokines
- Immunohistochemical Stains, and others.

- Analysis of major immunoassay analyzers used for
cancer diagnostic testing, including their operating characteristics,
features and selling prices.

Technology Review

- Assessment of monoclonal antibodies, immunoassays, DNA
probes, biochips/microarrays, chromosome analysis, IT,
artificial intelligence, flow cytometry, biosensors, and other technologies
and their potential applications for cancer diagnostic testing.

- Review of competing/complementing technologies, including
CT, MRI, NMR, PET and photonics spectroscopy.

- Extensive listings of over 500 companies, universities
and research centers developing new cancer diagnostic tests
and detection technologies.

Competitive Assessments

- Strategic assessments of major suppliers
and start-up firms developing innovative
technologies and products, including their sales,
product portfolios, marketing tactics, collaborative
arrangements, and new products in R&D.

Contains 585 pages and 95 tables

"Future Horizons and Growth Strategies in the French Cancer Diagnostics Market 2015” is a new strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years.  The report examines trends in the French cancer diagnostics markets; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers and market segment; profiles leading market players and potential entrants; and suggests alternative business expansion strategies for suppliers.

Table Of Contents

Future Horizons and Growth Strategies in the French Cancer Diagnostics Market 2015: Supplier Shares and Country Forecasts
I. Introduction
II. Worldwide Market Overview
1. Market Overview
2. Worldwide Market Structure
3. Worldwide Market Size and Growth
III. Major Product Development Opportunities
A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products
IV. Design Criteria for Decentralized Testing Products
V. Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies
VI. Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
Table of Contents (continues)

VII. Worldwide Market and Technology Overview
A. Cancer Statistics and Etiology
1. Breast Cancer
2. Lung Cancer
3. Colon and Rectum Cancer
4. Prostate Cancer
5. Stomach Cancer
6. Leukemia
7. Lymphoma
8. Oral Cancer
9. Skin Cancer
10. Uterine Cancer
11. Ovarian Cancer
12. Bladder Cancer
B. Major Current And Emerging Cancer Diagnostic Tests
1. Introduction
2. Tumor Marker Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembrionic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin
16. NSE
17. Occult Blood
18. PAP Smear/HPV
19. Prostatic Acid Phosphatase (PAP)
20. Prostate-Specific Antigen (PSA)
21. Squamous Cell Carcinoma Antigen (SCC)
22. T and B Lymphocytes
Table of Contents (continues)
23. TdT
24. Thyroglobulin
25. Tissue Polypeptide Antigen (TPA)
26. Biochemical Tumor Markers
27. Oncogenes
- Abl/abl-bcr
- AIB1
- BCL-2
- BRCA1
- CD44
- C-fos
- C-myb
- C-myc
- CYP-17
- Erb-B
- HPC1
- N-myc
- P40
- P51
- P53
- PIK3CA
- PTI-1
- Ras
- Reg
- Sis
- Src
28. Polypeptide Growth Factors
- Basic Fibroblast Growth Factor
- Beta-TGF
- Cachectin (TNT)
- Calmodulin
- ECFR
- Nerve Growth Factor (NGF)
- Epidermal Growth Factor (EGF)
- Ornithine Decarboxylase
- Transferrin
- Transforming Growth Factor-Alpha
Table of Contents (continues)

29. Ectopic Hormones
30. Colony Stimulating Factors
31. Lymphokines
- Alpha-Interferon
- B Cell Growth Factors
- B Cell Growth Factor (BCGF)
- Gamma-Interferon
- Interleukin-1 (IL-1)
- Macrophage Activating Factor
32. Immunohistochemical Stains
33. Emerging Tumor Markers
- N-Acetylglucosamine
- Actin
- Alpha-Actin
- Antineuronal Antibodies
- 7B2
- B72.3
- Bax
- BCD-F9
- BLCA-4
- Blood Group Antigens A,B,H
- CA 50
- CA 72-4/TAG-72
- CA 195
- CA-242
- CA-549
- CAM 26
- CAR-3
- Cathepsin-D
- Chromogranin A and B
- Cluster 1 Antigen
- Cluster-5/5A Antigen
- CTA
- CU18
- DR-70
- DU-PAN-2
- Endometrial Bleeding Associated Factor
- Endostatin
- Epithelial Membrane Antigen
- Feulgen Hydrolysis
- Fibronectin
Table of Contents (continues)
- FSH
- (1->3)-L-fucosyltransferase
- Gastrin-Releasing Peptide (GRP)
- GDCFP-15
- Glucagon
- Glycoamines
- H23
- Her-2
- Human Carcinoma Antigen
- HPA
- HSP27
- Intermediate Filaments
- Cytokeratins/CK18/Cyfra 21-1
- Desmin
- Gliofibrillary Acid Protein
- Neurofilaments
- Vimentin
- KA 93
- Kinases
- KP16D3
- LAI
- Leukocyte Common Antigen
- Lewis Antigens
- Lysophosphatidic Acid (LPA)
- Ma 695/Ma 552
- MABDF3
- MAG
- ME1
- Minactivin
- MN/CA9
- MSA
- Mucin Cancer Antigen (MCA)
- Multiple Tumor Suppressor 1
- Myosin
- NEA-130
- NMP22
- OA-519
- Opiod Peptides
- P-glycoprotein
- Pancreatic Oncofetal Antigen (POA)
- Placental Lactogen
- PR92
Table of Contents (continues)
- Proliferative Index, Ki-67
- Px
- RB Inactivation/Deletion
- Ret
- SCCL 175
- Selectin
- Sialic Acid
- Sialyl SSEA-1/SLX
- SN10
- Somatostatin
- TA-90
- TABA
- Tachykinin
- TAG 12
- TPS
- Troponin
- Tubulin
- VCAM
- VEGF
- Villen
C. Cancer Diagnostic Testing Instrumentation Review and Market Needs
D. Current and Emerging Cancer Diagnostic Technologies
1. Monoclonal and Polyclonal Antibodies
2. Immunoassays
3. Molecular Diagnostics
4. Chromosome Analysis
a. Chronic Myelogenous Leukemia (CML)
b. Acute Myeloid Leukemia (AML)
c. Acute Lymphoblastic Leukemia (ALL)
d. Malignant Lymphomas Lymphoid Malignancies
e. Chronic Lymphocytic Leukemia (CLL)
f. Solid Cancers
g. Chromosomal Translocation and Oncogenes
5. Artificial Intelligence
6. Flow Cytometry
7. Two Dimensional Gel Electrophoresis (2-DGE)
8. Biosensors
9. Competing/Complementing Technologies
E. Personal Testing
Table of Contents (continues)
VIII. France Cancer Diagnostics Market
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Test Volume and Sales Forecasts by Market Segment,
Major Supplier Sales and Market Shares by Test
IX. Competitive Profiles
- Abbott
- AdnaGen/Alere
- Agilent Technologies
- Applied Gene Technologies
- Arca Pharma
- Beckman Coulter/Danaher
- Becton Dickinson
- Biomedical Diagnostics
- bioMerieux
- Bio-Rad
- CellSearch
- Cepheid
- Correlogic Systems/Vermillion
- Decode Genetics
- Diadexus
- Diagnocure
- Diasorin
- Eiken Chemical
- Elitech Group
- Epigenomics
- Enterix
- Enzo Biochem
- Exact Sciences
- Fujirebio
- Guided Therapeutics
- Hologic/Gen-Probe
- Kreatech/Leica
- Kyowa Medex
- Mackay Life Sciences
- Myriad Genetics
- OncoLab
Table of Contents (continues)
- Ortho-Clinical Diagnostics
- Panacea Pharmaceuticals
- Polartechnics
- Polymedco
- PreMD
- Qiagen
- Quest Diagnostics
- Radient Pharmaceuticals
- Roche
- Scienion
- Sequenom
- Siemens Healthcare
- Takara Bio
- Targeted Diagnostics and Therapeutics
- Tosoh
- Thermo
- Veridex
- Wako Pure Chemicals
- Wallac/PE
- Zila

X. Appendix: Major Universities and Research
Centers Developing Cancer Diagnostic
Technologies and Applications



List of Tables

Tumor Marker Classification
Major Companies Developing or Marketing
ACTH Tests
Major Companies Developing or Marketing
AFP Tests
Major Companies Developing or Marketing
Beta-2 Microglobulin Tests
Major Companies Developing or Marketing
CA 15-3/27.29 Tests
Major Companies Developing or Marketing
CA 19-9 Tests
Major Companies Developing or Marketing
CA 125 Tests
Major Companies Developing or Marketing
Calcitonin Tests
Major Companies Developing or Marketing
CEA Tests
Major Companies Developing or Marketing
Estrogen Receptor Tests
Major Companies Developing or Marketing
Progesterone Receptor Tests
Major Companies Developing or Marketing
Ferritin Tests
Major Companies Developing or Marketing
Gastrin Tests


List of Tables (continues)
Major Companies Developing or Marketing
HCG Tests

Major Companies Developing or Marketing
Insulin Tests

Major Companies Developing or Marketing
NSE Tests
Major Companies Developing or Marketing
Occult Blood Tests
Major Companies Developing or Marketing
PAP Smear/HPV Tests
Major Companies Developing or Marketing
PAP Tests
Major Companies Developing or Marketing
PSA Tests
Major Companies Developing or Marketing
Lymphocyte Subclassification Tests
Biochemical Markers Potential Applications
In Cancer Diagnosis
Oncogenes Potential Applications
In Cancer Diagnosis
Major Companies Developing or Marketing
Oncogene Tests
Growth Factors Potential Applications
In Cancer Diagnosis
Colony Stimulating Factors Potential
Applications in Cancer Diagnosis
Lymphokines Potential Applications In Cancer Diagnosis


List of Tables (continues)
Immunohistochemical Stains Potential
Applications in Cancer Diagnosis
Executive Summary Table: France, Total Cancer
Diagnostic Test Volume and Sales Forecast
by Market Segment
France, Estimated Cancer Death Rates
Per 100,000 Population
France, Laboratories Performing Tumor
Marker Tests by Market Segment
France, Hospital Laboratories Performing
Tumor Marker Tests by Bed Size
France, Commercial/Private Laboratories
Performing Tumor Markers by Annual Test Volume
France, Total Tumor Marker Test Volume
Forecast by Market Segment
France, All Market Segments Major Tumor
Marker Test Volume Forecast
France, Hospital Laboratories Major Tumor
Marker Test Volume Forecast by Test
France, Commercial/Private Laboratories
Marker Test Volume Forecast
France, Total Tumor Marker Sales Major Tumor
Forecast by Market Segment
France, All Market Segments Major Tumor
Marker Sales Forecast by Test
France, Hospital Laboratories Major Tumor
Marker Sales Forecast by Test


List of Tables (continues)
France, Commercial/Private Laboratories Cancer
Diagnostics Market Forecast by Test
France, ACTH Test Volume and Diagnostics Sales
Forecast by Market Segment
France, AFP Test Volume and Diagnostics Sales
Forecast by Market Segment
France, Beta-2 Microglobulin Test Volume and
Diagnostics Sales Forecast by Market Segment

France, CA 15-3/27.29 Test Volume and
Diagnostics Sales Forecast by Market Segment
France, CA 19-9 Test Volume and Diagnostics
Sales Forecast by Market
France, CA-125 Test Volume and Diagnostics
Sales Forecast by Market Segment
France, Calcitonin Test Volume and Diagnostics
Sales Forecast by Market Segment
France, Cathepsin Test Volume and Diagnostics
Sales Forecast by Market Segment
France, CEA Test Volume and Diagnostics Sales
Forecast by Market Segment
France, Colon-Specific Antigen Test Volume
And Diagnostics Sales Forecast by Market Segment
France, Cytokeratins Test Volume and
Diagnostics Sales Forecast by Market Segment



List of Tables (continues)
France, Estrogen Receptor Test Volume and
Diagnostics Sales Forecast by Market
Segment
France, Ferritin Test Volume and
Diagnostics Sales Forecast by Market
Segment
France, Gastrin Test Volume and
Diagnostics Sales Forecast by Market
Segment
France, HCG Test Volume and Diagnostics Sales
Forecast by Market Segment
France, Insulin Test Volume and
Diagnostics Sales Forecast by Market
Segment
France, Interferons Test Volume and
Diagnostics Sales Forecast by Market
Segment
France, Interleukins Test Volume and
Diagnostics Sales Forecast by Market
Segment
France, Lymphocyte Subtyping Test Volume
And Diagnostics Sales Forecast by Market
Segment
France, NSE Test Volume and Diagnostics
Sales Forecast by Market Segment
France, Nucleolar Test Volume and Diagnostics
Sales Forecast by Market Segment
France, Occult Blood Test Volume and
Diagnostics Sales Forecast by Market
Segment


List of Tables (continues)
France, Oncogenes Test Volume and
Diagnostics Sales Forecast by Market
Segment
France, Pancreatic Oncofetal Antigen
Test Volume and Diagnostics Sales
Forecast by Market Segment
France, PAP Smear Test Volume and
Diagnostics Sales Forecast by Market
Segment
France, Parathyroid Hormone Test Volume and
Diagnostics Sales Forecast by Market
Segment
France, Progesterone Receptor Test Volume
And Diagnostics Sales Forecast by Market
Segment

France, PAP Test Volume and Diagnostics Sales
Forecast by Market Segment
France, PSA Test Volume and Diagnostics Sales
Forecast by Market Segment
France, S-100 Protein Test Volume and Sales
Diagnostics Sales Forecast by Market
Segment
France, Serotonin Test Volume and
Diagnostics Sales Forecast by Market
Segment
France, Sialic Acid Test Volume and
Diagnostics Sales Forecast by Market
Segment



List of Tables (continues)

France, Squamous Cell Carcinoma Antigen
Test Volume and Diagnostics Sales
Forecast by Market Segment
France, TDT Test Volume and Diagnostics Sales
Forecast by Market Segment
France, Thymidine Kinase Test Volume
And Diagnostics Sales Forecast by
Market Segment
France, Thyroglobulin Test Volume and
Diagnostics Sales Forecast by Market
Segment
France, TPA Test Volume and Diagnostics Sales
Forecast by Market Segment
France, Total Tumor Marker Sales
By Major Suppliers
France, AFP Testing Market Diagnostics
Sales by Major Supplier
France, CA 15-3 Testing Market Diagnostics
Sales by Major Supplier
France, CA 19-9 Testing Market Diagnostics
Sales by Major Supplier
France, CA 125 Testing Market Diagnostics
Sales by Major Supplier
France, CEA Testing Market Diagnostics
Sales by Major Supplier
France, NSE Testing Market Diagnostics
Sales by Major Supplier



List of Tables (continues)
France, PAP Testing Market Diagnostics
Sales by Major Supplier
France, PSA Testing Market Diagnostics
Sales by Major Supplier

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Cancer Diagnostics 2020: Supplier Shares and Strategies, Country Segment Forecasts, Technology Trends, Emerging Opportunities--Tumor Markers, Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

Cancer Diagnostics 2020: Supplier Shares and Strategies, Country Segment Forecasts, Technology Trends, Emerging Opportunities--Tumor Markers, Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

  • $ 21100
  • Industry report
  • October 2016
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100.  The report is available by country, section, market segment, and can be custom-tailored to your specific ...

Tumor Markers: Supplier Shares by Test, Competitive Strategies, Country Volume and Sales Segment Forecasts, Technology Trends, Instrumentation Review,  Emerging Opportunities--France, Germany, Italy, Japan, Spain, UK, US

Tumor Markers: Supplier Shares by Test, Competitive Strategies, Country Volume and Sales Segment Forecasts, Technology Trends, Instrumentation Review, Emerging Opportunities--France, Germany, Italy, Japan, Spain, UK, US

  • $ 21100
  • Industry report
  • October 2016
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100.  The report is available by country, section, market segment, and can be custom-tailored to your specific ...

Europe Tumor Marker Diagnostic Testing Market: Future Horizons and Growth Strategies--Instrument and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities

Europe Tumor Marker Diagnostic Testing Market: Future Horizons and Growth Strategies--Instrument and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities

  • $ 12800
  • Industry report
  • August 2016
  • by Venture Planning Group

This unique report provides information not available from any other published source, including volume, sales, and leading supplier shares by test. This comprehensive five-country report identifies and ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.